Parenteral nutrition-associated liver disease (PNALD) is a severe complication in patients completely dependent on parenteral nutrition (PN). The gold diagnostic standard, liver biopsy, is associated with significant health risk and therefore its use is limited. MicroRNAs (miRNAs) are small non-coding regulatory RNA molecules with highly tissue-specific expression and the secreted miRNAs may serve as non-invasive diagnostic biomarkers. The aim of this study was to evaluate the expression of a panel of specific miRNAs associated with liver diseases of different origin in PN-dependent adult patients in order to design miRNA panel enabling to precise monitoring of PNALD progression. Twelve PN-dependent patients with short bowel syndrome (SBS) were monitored on three/four-month basis for up to 24 months. Forty-five age-and sex-matched subjects without any known liver pathology served as controls. Specific miRNAs expression was determined by RT-qPCR using TaqMan probes (Thermofisher). Liver function test parameters were determined in certified clinical laboratories.
Long-term administration of total parenteral nutrition (PN) that is often associated with the development of parenteral nutrition-associated liver disease (PNALD). The origin of this pathologic condition is multifactorial with numerous contributing factors, such as sepsis, intestinal inflammation, cholangitis, cholelithiasis, bacterial translocation, short bowel syndrome, the disturbance of hepato-biliary circulation, the lack of enteral nutrition, etc.
PNALD clinical manifestations -which range from steatosis, cholestasis, gallbladder sludge/stones, fibrosis, and cirrhosis -can occur separately or in combination (Drongowski et al. 2009 , Luman et al. 2002 . The history of PNALD in adult patients is characterized by elevated liver enzymes in association with steatosis lasting for years, followed by steatohepatitis, cholestatic hepatitis as well as fibrosis and cirrhosis (Cahova et al. 2017 ). The exact staging of the disease progression is necessary for the determination of the right prognosis and efficient treatment, including the indication for the intestine transplantation. It was repeatedly shown that liver tests alone are not sensitive enough for the diagnosis (Klek et al. 2016) . Therefore, a liver biopsy remains the gold diagnostic procedure. Nevertheless, liver biopsy is associated with significant health risk and therefore its use is limited. There is an urgent need for seeking novel diagnostic tools for PNALD. These would help to optimize existing PN administration regimen/composition in order to delay or even prevent the development of PNALD. The aim of our study was to determine serum concentrations of selected miRNAs associated with liver pathologies of different origin in a cohort of adult PNdependent patients in order to design miRNA panel enabling to precise monitoring of PNALD progression. miRNAs are small endogenous RNA molecules that post-transcriptionally regulate gene expression by preferentially targeting the 3´-untranslated region of specific mRNA (Marin et al. 2014) . The specific miRNA/mRNA interaction typically results in negative regulation of the expression of the protein encoded by target mRNA (Grimson et al. 2007 ). The occurrence of miRNAs is not restricted into intracellular space, in contrast, they are found in extracellular body fluids like blood, milk, urine, cerebral spinal fluid, semen, saliva and bile (Shigehara et al. 2011) . Extracellular miRNAs are quite stable (Gori et al. 2014 ). Many of the circulating miRNAs are highly tissue-specific (Ninomiya et al. 2013 ) and emerging evidence shows that they can serve as non-invasive diagnostic biomarkers for various diseases, including nonalcoholic fatty liver disease (Yamada et al. 2013) , steatohepatitis (Jin et al. 2012) , biliary diseases (Munoz-Garrido et al. 2012) or hepatocellular cancer (Gailhouste et al. 2013 ).
We performed an extensive computer-based search of published articles in PubMed to identify relevant studies on the usefulness of serum miRNAs as non-invasive biomarkers for the detection of liver pathologies. The used Medical Subject Headings terms and keywords were "miRNA", "biomarker", "liver disease", "PNALD", "cholestasis" and "NASH". We found 52 miRNAs proposed as putative biomarkers of liver injury (Table 1) that were further analyzed in a cohort of adult patients with chronic intestinal failure.
The discovery cohort consisted of 12 subjects with short bowel syndrome of different etiologies who were repeatedly monitored on three/four-month basis for up to 24 months.
Underlying cause of SBS were mesenteric ischemia (n=4), Crohn disease (n=1), ulcerative colitis (n=1), Gardner syndrome (n=1), post radiation enteritis (n=3), postsurgical adhesion (n=1) and trauma (n=1). Control cohort included 45 apparently healthy age-and sex-matched subjects without any known liver pathology. Blood sample with no additives was taken between 7. -8. a.m. in a fasting state and it was left at room temperature for 30 min. Then it was centrifuged twice for 3000 g, 15 min, 4°C, serum removed to the new tube and centrifuged again 3000g, 10 min, 4°C in order to remove any blood elements. The serum was aliquoted and stored at -80°C until analysis. miRNA extraction was performed using miRCURY RNA isolation kit -biofluids (Exiqon) with RNA Carrier MS2 10 ng/ul ( Roche). miRNA detection system included specific Taqman MicroRNA Reverse Transcription kit and TaqMan microRNA assays (Thermofisher Scientific). The PCR reaction was performed on ViiA7 Real-Time PCR system (Thermofisher Scientific). The specific miRNA expression was normalized to Stock Serum/Plasma spike-in control Caenorhabditis elegans MIR39 (cel miR-39-3p), 2 x 10 6 molecules per sample (Qiagen). The data are expressed as 2 ΔCt (ΔCt = CtmiRNA -Ctcel miR-39) and presented as a median and interquartile range. Statistical analysis was performed using the Kruskal-Wallis test. Differences were considered statistically significant at the level of p < 0.05. Spearman's rank correlation coefficient was used to assess the correlation between the studied variables.
SBS patients represent a highly diverse cohort with respect to the primary diagnosis, duration of PN-dependence or age. Most of the patients (11 out of 12) exhibited chronically abnormal liver function tests (Table 2 ). Among all miRNAs tested, six exhibited significantly altered expression compared with healthy controls. Three of them (MIR122, MIR1273g, and MIR500a) were upregulated while three were down-regulated (MIR505, MIR199a, MIR139) in SBS patients. MIR122 positively correlated with s-AST and s-ALT activities while
MIR1273g positively correlated with s-CRP concentration and with s-GGT activity. MIR505, MIR199a, and MIR139 negatively correlated with s-GGT activity (Table 3) . Fluctuation of these parameters well paralleled serum miRNA concentrations in all patients throughout the whole observation period.
MIR122 is highly enriched in the liver but absent in other tissues (Lagos-Quintana et al. ( Roderburg et al. 2015) showed that serum MIR122 concentrations were strongly elevated in mice after hepatic ischemia/reperfusion injury, as well as in the cellular supernatants in an in vitro model of hepatocyte injury, supporting the hypothesis that the passive release of MIR122 represents a surrogate for hepatocyte death in liver injury. This finding corresponds with our observation that serum MIR122 levels correlate with ALT and AST concentrations. Taken together, MIR122 levels may serve as an independent marker of ongoing liver injury and hepatic cell death.
Serum content of all other miRNAs deregulated in PN-dependent patients significantly correlated with GGT serum activity, which is a marker of cholestasis. To our knowledge, this association has not been described yet. Three of these miRNAs (MIR199a, MIR505, and In conclusion, we identified a panel of six miRNAs differently expressed in sera of PNdependent patients with abnormal liver function tests compared with healthy controls. These miRNAs correlated with liver injury and hepatic cell death (MIR122), cholestasis (MIR505, MIR199a, MIR139, MIR500a, MIR1273g) or inflammation (MIR1273g). This study suggests that specific miRNAs profile in serum has potential as a diagnostic biomarker of PNALD progression.
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